Changes in global levels of individual histone modifications are predictive of the clinical outcome of prostate cancer independently of other features such as tumor stage, preoperative prostate-specific antigen levels, and capsule invasion [76], and may help to identify patients with adverse prognosis and high risk for recurrence [77, 78]. This evidence concerns the gene KLK3 and prostate carcinoma.